Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. (TOI) is positioned for positive financial growth due to its strategic partnership with Helios, which is anticipated to enhance margins significantly in 2026 and 2027 as contracts mature, aligning with a target margin range of 12%-15%. The company is expected to benefit from the expansion of the fee-for-service (FFS) segment, coupled with growth in new markets, while integrating its dispensary and pharmacy services within its clinics to create a higher-margin revenue stream. Additionally, the elimination of the DIR fee has improved cost visibility and is projected to enable margin recovery in 2025, further solidifying TOI's favorable profitability outlook.

Bears say

The Oncology Institute faces significant pressure on its gross margins following contract losses in 2024, which may adversely affect the company's financial health as new contracts slowly ramp up. Additionally, the expected declines in coverage and pressures from payer partners could further strain revenues, with growth rates anticipated to lag behind the overall industry average. Dispensary margins have already been negatively impacted by the elimination of DIR fees, representing a $15 million setback, while the company's historical EBITDA losses raise concerns about its ability to achieve financial stability in the near term.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.